- ISIN
- US8693671021
- CUSIP
- 869367102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 27, 2018
Highlights
- Market Cap
- $355.58M
- Enterprise Value
- $303.13M
- EPS (TTM)
- -$15.91
- Total Revenue (TTM)
- $99.61M
- Gross Profit (TTM)
- $83.46M
- EBITDA (TTM)
- -$105.17M
- Year Range
- $6.74 - $43.85
- Target Price
- $50.00
- ROA (TTM)
- -63.48%
- ROE (TTM)
- 229.64%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
STRO Performance Chart
Sutro Biopharma, Inc. (STRO) is up 134.9% since the beginning of the year. At $27 per share, STRO is trading 38.0% below its 52-week high of $44. Investors who bought $1,000 worth of STRO shares 5 years ago would now be looking at an investment worth $147.
Loading charts...
Returns By Period
Sutro Biopharma, Inc. (STRO) has returned 134.92% so far this year and 197.60% over the past 12 months.
Sutro Biopharma, Inc.
- 1D
- 11.26%
- 1M
- -29.20%
- YTD
- 134.92%
- 6M
- 212.41%
- 1Y
- 197.60%
- 3Y*
- -16.80%
- 5Y*
- -31.81%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
STRO Monthly Returns History
Based on dividend-adjusted daily data since Sep 27, 2018, STRO's average daily return is +0.06%, while the average monthly return is +0.47%. At this rate, an investment would double in approximately 12.3 years.
Historically, 48% of months were positive and 52% were negative. The best month was Dec 2023 with a return of +64.4%, while the worst month was Mar 2025 at -59.1%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.
On a daily basis, STRO closed higher 47% of trading days. The best single day was Apr 24, 2025 with a return of +44.4%, while the worst single day was Mar 16, 2020 at -39.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 29.21% | 36.92% | 21.69% | 47.01% | -20.18% | -7.01% | 134.92% | ||||||
| 2025 | 4.35% | -17.19% | -59.08% | 61.39% | -14.50% | -20.47% | 12.80% | 6.43% | 1.32% | 28.97% | -17.91% | 25.84% | -37.12% |
| 2024 | 1.17% | 13.13% | 15.07% | -39.91% | 24.45% | -30.65% | 35.49% | 15.11% | -24.29% | -6.07% | -18.46% | -30.57% | -57.11% |
| 2023 | -10.40% | -22.10% | -18.09% | -7.79% | 5.40% | 3.56% | -3.87% | 6.26% | -26.95% | -20.75% | -5.09% | 64.37% | -46.91% |
| 2022 | -28.23% | -16.48% | -7.85% | -26.89% | -27.62% | 19.77% | 12.28% | -3.25% | -1.94% | 32.07% | 2.18% | 7.88% | -45.70% |
| 2021 | 2.03% | 0.23% | 2.52% | -9.89% | -9.26% | -0.11% | -8.39% | 27.54% | -13.03% | 6.72% | -15.28% | -12.88% | -31.46% |
Benchmark Metrics
Sutro Biopharma, Inc. has an annualized alpha of -6.83%, beta of 1.46, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 28, 2018.
- This stock participated in 163.40% of S&P 500 Index downside but only 45.13% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -6.83%
- Beta
- 1.46
- R²
- 0.11
- Upside Capture
- 45.13%
- Downside Capture
- 163.40%
Return for Risk
Risk / Return Rank
STRO ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Sutro Biopharma, Inc. (STRO) and compare them to S&P 500 Index.
| STRO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.03 | ||
| Sortino ratioReturn per unit of downside risk | -0.36 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.41 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 4.94 | 2.93 | +2.01 |
| Martin ratioReturn relative to average drawdown | 13.36 | 13.52 | -0.16 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sutro Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sutro Biopharma, Inc. was 98.10%, occurring on Apr 17, 2025. The portfolio has not yet recovered.
The current Sutro Biopharma, Inc. drawdown is 90.13%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.10%Apr 2025 | 4y 2mo | — | 5y 4moJan 2021 - now |
COVID crash2020 | -59.28%Mar 2020 | 1y 5mo | 7mo 25d | 2y 1moSep 2018 - Nov 2020 |
2021 correction2021 | -13.55%Jan 2021 | 17d | 3d | 20dDec 2020 - Jan 2021 |
2020 correction2020 | -12.49%Nov 2020 | 5d | 11d | 16dNov 2020 - Dec 2020 |
2020 pullback2020 | -8.27%Nov 2020 | 0s | 3d | 3dNov 2020 - Nov 2020 |
Drawdown Indicators
| STRO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.10% | -56.78% | -41.32% |
Max Drawdown (1Y)Largest decline over 1 year | -40.28% | -9.10% | -31.18% |
Max Drawdown (3Y)Largest decline over 3 years | -90.72% | -18.90% | -71.82% |
Max Drawdown (5Y)Largest decline over 5 years | -97.77% | -25.43% | -72.34% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -90.13% | -0.74% | -89.39% |
Average DrawdownAverage peak-to-trough decline | -61.24% | -10.72% | -50.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.90% | 1.97% | +12.93% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sutro Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Sutro Biopharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for STRO relative to other companies in the Biotechnology industry. Currently, STRO has a P/S ratio of 2.6. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with STRO
Add Sutro Biopharma, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with STRO